UK markets closed
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • FTSE 250

    20,372.52
    +123.78 (+0.61%)
     
  • AIM

    968.25
    +10.25 (+1.07%)
     
  • GBP/EUR

    1.1764
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • BTC-GBP

    22,723.25
    -667.04 (-2.85%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • DOW

    33,212.96
    +575.77 (+1.76%)
     
  • CRUDE OIL

    115.07
    +0.98 (+0.86%)
     
  • GOLD FUTURES

    1,857.30
    +3.40 (+0.18%)
     
  • NIKKEI 225

    26,781.68
    +176.84 (+0.66%)
     
  • HANG SENG

    20,697.36
    +581.16 (+2.89%)
     
  • DAX

    14,462.19
    +230.90 (+1.62%)
     
  • CAC 40

    6,515.75
    +105.17 (+1.64%)
     

The Worldwide Cognitive and Memory Enhancer Drugs Industry is Expected to Reach $8.6 Billion by 2030

·7-min read
Company Logo
Company Logo

Global Cognitive and Memory Enhancer Drug Market

Global Cognitive and Memory Enhancer Drug Market
Global Cognitive and Memory Enhancer Drug Market

Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "Cognitive and Memory Enhancer Drugs Market by Product, Application: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The global cognitive and memory enhancer drug market was valued at $5,079.86 million in 2020, and is projected to reach $8,689.74 million by 2030, registering a CAGR of 5.5% from 2021 to 2030. Cognitive and memory enhancer drugs, supplements, and other substances are claimed to improve cognitive function, particularly executive functions, attention, memory, creativity, or motivation, in healthy individuals. These drugs include a number of different kinds of substances that can increase mental performance and capable of improving or preserving memory, of potentiating learning, or of preventing cognitive decline or dementia.

The major factors that contribute to the market growth include surge in geriatric population, which is highly prone to neurological disorders such as Alzheimer's. Moreover, rise in adoption of cognitive drugs, owing to their benefits such as improved physical and mental performance, boosts the market growth. However, ethical issues related with the use of such drugs restrain the growth of this market.

The cognitive and memory enhancer drug market is segmented into product, application, and region. By product, the market is fragmented into Aricept, Exelon, Namenda, Razadyne, Provigil, Ritalin, Adderall, and others. By application, it is segregated into disease treatment, education, sports, and others. Region wise, the cognitive and memory enhancer drug market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global cognitive and memory enhancer drug market include AbbVie, Alterna Script LLC, Ceretropic, Biogen., Johnson & Johnson, Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., Torrent Pharmaceutical, Inc., and Teva Pharmaceutical Industries Ltd. (Cephalon Inc.).

Key Benefits

  • The report provides an in-depth analysis of the global cognitive and memory enhancer drug market size along with the current trends and future estimations to elucidate the imminent investment pockets

  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market

  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities

  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global cognitive and memory enhancer drug market

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Winning Strategies
3.2.2. Top Investment Pockets
3.3. Market Share Analysis, 2020
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rapid Growth of Geriatric Population
3.4.1.2. High Incidence of Neurodegenerative Disorders
3.4.1.3. Benefits of Smart Drugs
3.4.2. Restraint
3.4.2.1. Numerous Ethical Issues
3.4.3. Opportunity
3.4.3.1. Effective Strength of the Drugs
3.4.4. Impact Analyses
3.4. Covid-19 Impact Analysis

Chapter 4: Cognitive and Memory Enhancer Drugs Market, by Product
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Aricept
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Exelon
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Namenda
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Razadyne
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
4.6. Provigil
4.6.1. Key Market Trends, Growth Factors, and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Analysis, by Country
4.7. Ritalin
4.7.1. Key Market Trends, Growth Factors, and Opportunities
4.7.2. Market Size and Forecast, by Region
4.7.3. Market Analysis, by Country
4.8. Adderall
4.8.1. Key Market Trends, Growth Factors, and Opportunities
4.8.2. Market Size and Forecast, by Region
4.8.3. Market Analysis, by Country
4.9. Others
4.9.1. Key Market Trends, Growth Factors, and Opportunities
4.9.2. Market Size and Forecast, by Region
4.9.3. Market Analysis, by Country

Chapter 5: Cognitive and Memory Enhancer Drugs Market, by Application
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Disease Treatment
5.2.1. Market Size and Forecast, by Type
5.2.1.1. Developmental Conditions
5.2.1.1.1. Market Size and Forecast
5.2.1.2. Neurodegenerative Disorders
5.2.1.2.1. Market Size and Forecast
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Analysis, by Country
5.3. Academic Performance
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Athletic Performance
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country
5.5. Others
5.5.1. Market Size and Forecast, by Region
5.5.2. Market Analysis, by Country

Chapter 6: Cognitive and Memory Enhancer Drugs Market, by Region

Chapter 7: Company Profile
7.1. Allergan plc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.1.6. Key Strategic Moves and Developments
7.2. Alternascript LLC
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.3. Biogen.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.3. Ceretropic
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Opreating Segmentt
7.3.4. Product Portfolio
7.4. Biogen.
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves and Developments
7.5. Johnson & Johnson
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves and Developments
7.6. Novartis International AG
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.6.6. Key Strategic Moves and Developments
7.7. Pfizer Inc.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Torrent Pharmaceutical, Inc.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.9. Takeda Pharmaceutical Company Ltd.
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves and Developments
7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance

For more information about this report visit https://www.researchandmarkets.com/r/h9zfiq

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting